Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artiva Biotherapeutics, Inc. - Common Stock (NQ:ARTV)

7.610 -0.020 (-0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 237,463
Open 7.620
Bid (Size) 8.160 (100)
Ask (Size) 8.290 (200)
Prev. Close 7.630
Today's Range 7.450 - 7.780
52wk Range 1.470 - 14.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+79.9%
+79.9%
1 Month
-29.2%
-29.2%
3 Month
+51.3%
+51.3%
6 Month
+112.6%
+112.6%
1 Year
+286.3%
+286.3%

More News

Read More
News headline image
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Via FinancialNewsMedia
News headline image
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Myseum (NASDAQ: MYSE) Realizes $6.8M in Asset Sale – Watch AMCI, ARTV, QIPT, SURG Today!
Via AB Newswire
News headline image
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Which stocks are gapping on Monday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
4 Biotech Stocks Lifting Off As Momentum Builds ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Artiva Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Artiva Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Artiva Biotherapeutics, Inc. - Common Stock trade on?
Artiva Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock is ARTV on the Nasdaq Stock Market
What is the current price of Artiva Biotherapeutics, Inc. - Common Stock?
The current price of Artiva Biotherapeutics, Inc. - Common Stock is 7.610
When was Artiva Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Artiva Biotherapeutics, Inc. - Common Stock was at 05/28/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.